A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Arvinas Inc.
Myeloid Therapeutics
xCures
DualityBio Inc.
Seagen Inc.
Apollo Therapeutics Ltd
Alaunos Therapeutics
Massive Bio, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Travera Inc
Elicio Therapeutics
TCR2 Therapeutics
TCR2 Therapeutics
Merck Sharp & Dohme LLC
Toray Industries, Inc
Alaunos Therapeutics
Alaunos Therapeutics
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
Elevation Oncology
Singlera Genomics Inc.
Zymeworks BC Inc.
Symphogen A/S
Travera Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Convalife (Shanghai) Co., Ltd.
ABM Therapeutics Corporation
Beijing Kejing Biotechnology Co., Ltd.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
NextCure, Inc.
Celon Pharma SA
Hoffmann-La Roche
Klus Pharma Inc.
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
SpeciCare
BIND Therapeutics
AstraZeneca